Tyrosine-kinase inhibitor (TKI) therapy for human cancers is not curative, and relapse occurs owing to the continued presence of tumor cells, referred to as minimal residual disease (MRD). The survival of MRD stem or progenitor cells in the absence of oncogenic kinase signaling, a phenomenon referred to as intrinsic resistance, depends on diverse growth factors. Here we report that oncogenic kinase and growth-factor signaling converge to induce the expression of the signaling proteins FBJ osteosarcoma oncogene (c-FOS, encoded by Fos) and dual-specificity phosphatase 1 (DUSP1). Genetic deletion of Fos and Dusp1 suppressed tumor growth in a BCR-ABL fusion protein kinase-induced mouse model of chronic myeloid leukemia (CML). Pharmacological inhibition of c-FOS, DUSP1 and BCR-ABL eradicated MRD in multiple in vivo models, as well as in mice xenotransplanted with patient-derived primary CML cells. Growth-factor signaling also conferred TKI resistance and induced FOS and DUSP1 expression in tumor cells modeling other types of kinase-driven leukemias. Our data demonstrate that c-FOS and DUSP1 expression levels determine the threshold of TKI efficacy, such that growth-factor-induced expression of c-FOS and DUSP1 confers intrinsic resistance to TKI therapy in a wide-ranging set of leukemias, and might represent a unifying Achilles' heel of kinase-driven cancers.
Protein kinases are frequently activated in a variety of human cancers and represent attractive drug targets. In this regard, chronic myeloid leukemia (CML) represents an important paradigm, given that the success of imatinib in treating patients with CML provided proof of concept for targeted anti-kinase therapy and paved the way for the development of TKI therapy for several solid tumor types 1, 2 . Despite the impressive response to TKI therapy in the clinic, it is not curative because a small population of cancer cells are insensitive to treatment, manifesting as minimal residual disease (MRD) 3 . The cells responsible for MRD in CML are referred to as leukemia-initiating cells (LICs), whereas those responsible for MRD in solid tumors are referred to as cancer stem cells (CSCs). In ~50-60% of patients with CML, continuous drug treatment is needed to prevent MRD cells from reinstating the disease [4] [5] [6] . MRD cells serve as a reservoir that can develop TKI resistance by acquiring mutations or by activating alternative survival mechanisms [7] [8] [9] . Even the most potent kinase inhibitors are ineffective against LICs that are present in MRD 3, 10 .
Oncogene addiction refers to the exquisite dependence of transformed cells on a single mutant protein or signaling pathway for survival and proliferation 11 . The therapeutic response to TKIs is mediated by oncogene addiction to mutant tyrosine-kinase oncoproteins [11] [12] [13] . Multiple theories, including signaling-network dysregulation, synthetic lethality 14, 15 , genetic streamlining 16, 17 , and oncogenic shock 18, 19 , have attempted to explain how cells become oncogene addicted and how acute inhibition of an oncoprotein induces cell death. However, it is still not understood how MRD cells that do not respond to TKI therapy escape addiction to the driver oncogene. Recent studies have revealed that growth-factor signaling mediates resistance to TKI therapy in both leukemia and solid organ tumors [20] [21] [22] , but it remains to be determined whether intrinsic resistance conferred by a diverse set of growth factors utilizes distinct or shared molecular pathways. For instance, interleukin (IL)-3, IL-6, stem cell factor (SCF), fms-like tyrosine kinase 3 ligand (FLT3L) and granulocyte colony-stimulating factor (G-CSF) signaling in CML progenitor cells confer intrinsic resistance to imatinib. Similarly, hepatocyte growth factor (HGF) and neuregulin 1 (NRG1) signaling confer intrinsic resistance to protooncogene protein B-raf (BRAF) and epidermal growth factor receptor (EGFR) inhibitors in solid tumors [20] [21] [22] .
RESULTS

Growth-factor-induced expression of c-FOS and DUSP1 confers TKI resistance
To understand how growth-factor signaling induces intrinsic resistance to TKI treatment, we modeled growth-factor-induced-mitigation of TKI response using the IL-3-dependent BaF3 mouse cell line. We generated BaF3 cells with tetracycline-inducible expression of BCR-ABL (BaF3-LTBA; Fig. 1a ), as well as cells with constitutive BCR-ABL expression (BaF3-BA 9 ). Imatinib treatment of both BaF3-LTBA cells and BaF3-BA cells caused cell death, whereas the addition of IL-3 conferred resistance to imatinib, even in the case of sustained inhibition of BCR-ABL enzymatic activity ( Fig. 1b-d and Supplementary Fig. 1a) . Similarly, erythropoietin treatment conferred imatinib resistance in the human BCR-ABL + cell line K562 (an erythromyeloblastoid leukemia cell line derived from a patient with blast-crisis CML; Fig. 1e and Supplementary Fig. 1b ). Thus, we were able to recapitulate cytokine and/or growth-factor-induced resistance to imatinib in vitro.
We hypothesized that expression of the critical genes mediating TKI resistance would be modulated by BCR-ABL, growth-factor signaling, and TKI treatment. We therefore compared the expression profiles of BCR-ABL-induced BaF3-LTBA cells with and without IL-3 treatment (192 genes were differentially expressed; Supplementary Fig. 1c) , as well as imatinib-treated BaF3-BA cells with and without IL-3 (308 genes were differentially expressed; Supplementary Fig. 1d ). Next, we evaluated erythropoietin-modulated gene expression in imatinib-treated K562 cells (1,338 genes were differentially expressed; Supplementary Fig. 1e ). Finally, we analyzed existing gene-expression profiles from primary bone marrow (BM)-derived BCR-ABL + CD34 + cells collected from patients with CML before and after 1 week of imatinib treatment 23 , and we identified genes that were differentially expressed in the surviving marrow cells (85 genes were differentially expressed; Supplementary Fig. 1f ). When these four data sets were compared, only three differentially expressed genes were common to all comparisons: FOS (also known as c-FOS), dual-specificity phosphatase-1 (DUSP1) and ZFP36 ( Fig. 1f and Supplementary  Fig. 1g ). c-Fos belongs to the family of activator protein 1 (AP1) transcription factors implicated in the regulation of cell proliferation, survival, apoptosis, transformation, and oncogenesis 24 . DUSP1 is a nuclear protein that provides feedback regulation to MAPK signaling by inactivating MAPKs 25 and has been implicated in the regulation of inflammation, immune regulation, and chemoresistance in cancer 25, 26 . ZFP36 is an RNA-binding protein that has been implicated in cancer development, inflammation, and immune functions 27 .
In support of the hypothesis that oncogenic and growth-factor signaling modulate Fos, Dusp1, and Zfp36 expression, we found that both BCR-ABL and imatinib induced expression of these genes in BaF3-BA cells ( Fig. 1g-i) . Similarly, expression analysis of patient samples from chronic and blast-phase CML revealed higher (2-10-fold) expression of FOS, DUSP1, and ZFP36 as compared to that in normal CD34 + cells ( Fig. 1j ; the CML patient samples used in this study are described in Supplementary Table 1 ). Whereas treatment with imatinib alone downregulated the expression of these genes, treatment with imatinib plus growth factor (IL-3) resulted in 4-5-fold higher expression of these genes, as compared to BaF3-BA plus imatinib ( Fig. 1g) . In the absence of IL-3, ectopic expression of either c-Fos or Dusp1 led to modest resistance to imatinib, whereas ectopic expression of ZFP36 did not have an effect ( Supplementary  Fig. 2a,b ). However, similarly to IL-3, ectopic expression of Fos, Dusp1, and Zfp36 together in BaF3-BA cells impaired the inhibitory effect of imatinib on cell survival (Supplementary Fig. 2b) . Conversely, the depletion of Fos, Dusp1, and Zfp36 (either each alone or in combination) by shRNA-mediated knockdown reduced BCR-ABL-dependent proliferation and survival in BaF3-BA cells, whereas parental BaF3 cells were not affected ( Supplementary Fig. 2c-f) . These results suggest that Fos, Dusp1, and Zfp36 are functional mediators of growthfactor-induced imatinib resistance. Furthermore, knockdown of Fos and Dusp1 alone or together sensitized BaF3-BA cells to imatinib, even in the presence of IL-3 ( Supplementary Fig. 2g ). However, the depletion of Zfp36 sensitized parental BaF3 and BaF3-BA cells equally to imatinib, which suggests that, unlike Fos and Dusp1, Zfp36 is not differentially required by BCR-ABL-expressing cells. Therefore, we focused subsequent analyses on Fos and Dusp1.
Deletion of Fos and Dusp1 abrogates intrinsic TKI resistance
To determine the roles of c-Fos and Dusp1 in BCR-ABL-induced leukemogenesis, we determined the effects of the deletion of either Dusp1 −/− (ref. 28) or Fos fl/fl (ROSACre ERT2 Fos fl/fl ) (ref. 29), or both genes (ROSACre ERT2 Fos fl/fl ;Dusp1 −/− ). We used hematopoietic Kit + cells transduced with BCR-ABL-Ires-YFP retroviruses for in vitro colony-forming unit (CFU) assays and for generating an in vivo model of CML ( Fig. 2a) . Genetic deletion of Fos or Dusp1 significantly reduced (by 50%) the number of CFUs generated by BCR-ABL-expressing Kit + cells, whereas CFU generation by control cells (Kit + cells transduced with a MSCV-Ires-YFP virus) was not affected (Fig. 2b,c) . The deletion of Fos and Dusp1 alone sensitized BCR-ABL-expressing Kit + cells to imatinib treatment (~80% reduction, as compared to 50% reduction in wild-type (WT) controls). Strikingly, the deletion of both Fos and Dusp1 suppressed the number of CFUs generated by BCR-ABL expressing cells (~90%), and treatment with imatinib completely eradicated BCR-ABL-positive colonies ( Fig. 2d,e ). For analysis in vivo, mice were transplanted with 40,000 Kit + BM cells expressing BCR-ABL and YFP. Recipient mice developed fatal leukemia with a disease latency of 2-3 weeks 30 . Imatinib treatment did not result in a significant reduction in leukemic burden as compared to vehicle treatment, and all mice died in 3-4 weeks ( Fig. 2f,g) . By contrast, the deletion of Dusp1 delayed BCR-ABL-induced leukemia by 1 week, and deletion of Fos led to a disease latency of 7-8 weeks ( Fig. 2f-i) .
Notably, imatinib treatment of mice transplanted with c-Fos-deficient cells for 1 month led to a significant reduction in leukemic burden (to 0.5-4%); ~50% of mice survived, and treatment discontinuation did not result in disease relapse ( Fig. 2h,i) , which suggests that TKIresistant MRD was eliminated. In control experiments in which Fos was not deleted (using non-tamoxifen-treated ROSACre ERT2 Fos fl/fl donor cells), recipients showed disease-latency periods similar to those observed in WT mice in both imatinib-treated and untreated groups (Supplementary Fig. 3a,c) .
The deletion of both Fos and Dusp1 had a greater effect than deletion of either gene alone, rescuing ~60% of the mice from leukemic death and significantly reducing leukemic burden ( Fig. 2j,k) . Control ROSACre ERT2 Fos fl/fl ;Dusp1 −/− mice, not treated with tamoxifen, showed modestly prolonged survival as compared to WT controls ( Supplementary Fig. 3b,d) , which was correlated with lower Fos mRNA expression ( Supplementary Fig. 3e ). Deletion of both Fos and Dusp1, when combined with a 5-week course of imatinib treatment, eradicated all leukemic cells from peripheral blood and bone marrow, and discontinuation of treatment did not result in disease relapse, as assessed by YFP + cell burden in blood and bone marrow at the end of the experiment, 4 months after tumor cell transplantation (Fig. 2j,k) . Thus, genetic deletion of Fos and Dusp1 sensitizes BCR-ABL-expressing cells (but not WT cells) to imatinib treatment and eliminates TKI-resistant MRD. Moreover, the deletion of Fos and Dusp1 in ROSACre ERT2 Fos fl/fl ;Dusp1 −/− mice by tamoxifen injection did not show any apparent hematopoietic defects, and c-Fos-and Dusp1deficient cells were maintained in the peripheral blood and bone marrow ( Supplementary Fig. 3f ), which supports the concept that these genes are required for BCR-ABL-induced transformation and leukemia development but are dispensable for normal hematopoiesis.
To test whether c-Fos is required for the maintenance of disease, we deleted Fos after the onset of disease (3 weeks after tumor cell transplantation). At 2 weeks after transplantation, both WT and ROSACre ERT2 Fos fl/fl ;Dusp1 −/− mice showed an increase in granulocytes (~70-80% of peripheral blood cells, as compared to 32% in WT controls) at the expense of B cells ( Supplementary Fig. 3g ) As shown above, the deletion of both Fos and Dusp1 at week 3 rescued ~60% of the mice from leukemia (Supplementary Fig. 3h ). Imatinib treatment rescued mice transplanted with Fos-and Dusp1-deleted cells expressing BCR-ABL from leukemia and led to rapid clearance of the leukemic cells. Whereas non-imatinib-treated mice transplanted with cells expressing BCR-ABL in which Fos and Dusp1 had been deleted showed gradual depletion of leukemic cells, vector-only control cells not expressing BCR-ABL with the same deletion showed stable engraftment ( Supplementary Fig. 3h,i) . Taken together, these data suggest that genetic loss of Fos and Dusp1 together sensitizes leukemic cells to TKI in CML and confers synthetic lethality to BCR-ABLtransformed cells, given that leukemic cells are gradually depleted even without TKI treatment.
To rule out potential nonspecific effects of Fos or Dusp1 deletion on BCR-ABL-induced leukemia, we performed two additional experiments. First, we expressed a dominant-negative c-FOS (lacking the DNA-binding domain 31 ; Fig. 2l ,m) together with BCR-ABL in WT C57BL/6 bone marrow cells. Expression of dominant-negative c-FOS had effects that were similar to those observed for Fos deletion; i.e., >50% reduction in the number of BCR-ABL-dependent CFUs (Fig. 2n) . Second, expression of WT c-FOS partially rescued the phenotype, whereas expression of both c-FOS and Dusp1 using a monocistronic vector (P2A peptide cleavage) restored CFU numbers to normal levels ( Fig. 2o) .
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Inhibition of c-Fos, Dusp1, and BCR-ABL by small-molecule inhibitors cures mice of CML
To test the potential of targeting c-Fos and Dusp1 for therapy, we performed in vitro and in vivo experiments using small-molecule inhibitors of c-Fos and Dusp1 (Fig. 3a) . CFU analysis of BCR-ABL-LSK cells (bone-marrow-derived Lin -Sca1 + Kit + (LSK) cells represent hematopoietic stem and progenitor cells) treated with c-Fos and Dusp1 inhibitors recapitulated the genetic data. Specifically, combined treatment with a Dusp1 and Dusp6 inhibitor ((E)-2benzylidene-3-(cyclohexylamino)-2,3-dihydro-1H-inden-1-one; BCI 32 ), a c-Fos inhibitor (curcumin 33 ) and a BCR-ABL inhibitor (imatinib) completely suppressed CFU formation (imatinib + curcumin + BCI; Supplementary Fig. 4a,b) . To address the possibility of off-target effects of curcumin, we tested two other chemically distinct compounds targeting c-Fos: nordihydroguaiaretic acid 34 (NDGA) and difluorinated curcumin 35 (DFC). Both NDGA and DFC (imatinib + NDGA + BCI and imatinib + DFC + BCI) were effective at suppressing BCR-ABL-dependent CFU formation ( Fig. 3b and Supplementary  Fig. 4c ), which suggests that c-Fos is the relevant target of these compounds. Next, we examined the efficacy of these compounds in vivo by using a retroviral bone marrow transduction transplantation leukemogenesis model. A 1-month course of treatment with individual compounds with imatinib (BCI, curcumin, and NDGA) or without imatinib (BCI and curcumin) did not effectively treat leukemogenesis; however, treatment with imatinib + curcumin + BCI and imatinib + NDGA + BCI rescued 50% and 60% of the recipient mice, respectively ( Supplementary Fig. 4d ). By contrast, a 1-month course of treatment with imatinib + DFC + BCI rescued ~90% of mice, and we were unable to detect MRD by flow cytometry (Fig. 3c,d) .
Given the lack of MRD in the treated mice, we next wished to test the effectiveness of c-Fos and Dusp1 inhibition in a tumor model in which leukemic stem cells drive leukemogenesis. To this end, we used transgenic mice in which the 3′ enhancer of the Scl gene drives expression of the tetracycline transactivator (tTA) to regulate tet-0-BCR-ABL transgene expression in hematopoietic stem and progenitor cells 36 (Fig. 3e) . We transplanted 3,000-5,000 bone marrow LSK cells into irradiated BoyJ mice, which developed leukemia within 4-6 weeks. 4 weeks after transplantation, drug treatment was started (Fig. 3f) . Treatment with imatinib alone for 3 months resulted in a reduction (~60%) of CML cells in the bone marrow; however, a substantial percentage of BCR-ABL-positive cells were present in the bone marrow ( Fig. 3g) . Moreover, when treatment was discontinued, disease relapse occurred in all mice, replicating the clinical course of TKI therapy in CML (Fig. 3g) . By contrast, not only did treatment with imatinib + DFC + BCI for 3 months eradicate the donor-derived BCR-ABL-positive leukemic cells (CD45.2) in the bone marrow, but no relapse occurred when treatment was discontinued ( Fig. 3g and Supplementary  Fig. 5a-c) . Similarly to the retroviral CML model (Fig. 3c) , treatment with imatinib + curcumin + BCI or imatinib + NDGA + BCI resulted in effective eradication of CML stem progenitor cells, but a few recipient mice in these treatment groups relapsed once treatment was discontinued (Supplementary Fig. 5c ). Taken together, these results suggest that treatment with imatinib + DFC + BCI is more efficient than the combinations (imatinib + BCI + curcumin or imatinib + BCI + NDGA) at targeting leukemic stem cells that persist in MRD, perhaps owing to superior pharmacokinetics of DFC over curcumin 35 .
Inhibition of c-FOS and DUSP1 sensitizes patient-derived LICs to imatinib To extend these findings to human cells, we tested the effect of c-FOS and DUSP1 inhibition on the survival of primary CML patient samples ( Supplementary Table 1 ). Mice transplanted with 3,000 CD34 + cells from the primary patient sample CP4 showed robust cell engraftment within 2 weeks (Fig. 4a,b) . Drug treatment was started 2 weeks after transplantation and continued for a period of 4-6 weeks, using imatinib alone, DFC and BCI, or imatinib + DFC + BCI. As expected, treatment with imatinib + DFC + BCI for 3 weeks resulted in effective inhibition of leukemic cells, whereas treatment with imatinib alone or DFC + BCI was ineffective (Fig. 4b) .
As previously reported 37 , leukemic engraftment in this model is not stable, and most mice lost grafts within 7-8 weeks after transplantation ( Supplementary  Fig. 5d ), which precluded further investigation of the effect of drug treatment on MRD. Next, to test the efficacy of these drugs on primitive LSCs, we performed long-term-culture-initiating cell (LTC-IC) assays, a stringent in vitro assay for the detection of primitive hematopoietic or leukemic stem cells, using mononuclear cells from the CP1 sample, CD34 + cells from the CP4 sample, and CD34 + cells from a healthy donor as a control. As expected, LTC-IC activity was increased in imatinib-treated CP1 cells as compared to the vehicle-treated controls (Fig. 4c) , in agreement with previous studies 38 . However, imatinib treatment of sample CP4 showed a significant decrease in LTC-IC activity as compared to the vehicletreated controls (Fig. 4c) . Although the basis for the sensitivity of the CP4 sample to imatinib is unknown-perhaps underlying patientspecific genetic or epigenetic changes confer TKI sensitivity-the difference in the responses between these two samples underscores the heterogeneous nature of LSCs in the context of TKI therapy. Notably, treatment with DFC + BCI did not affect LTC-IC activity in leukemic or normal cells (Fig. 4c) . As expected, treatment with DFC + BCI + imatinib selectively eradicated the LTC-IC activity of leukemic cells (Fig. 4c) ; however, as opposed to the results with genetic deletion, this drug treatment partially inhibited normal cell growth, perhaps owing to off-target toxicity. Taken together, these results provide evidence that a combination of DFC + BCI + imatinib selectively targets CML stem and progenitor cells but spares normal CD34 + cells.
c-Fos and Dusp1 deficiency alters the AP1-regulated networks
Given that curcumin and its analogs target many different proteins in addition to c-Fos, we compared the effects of chemical inhibition and genetic loss of c-Fos on gene expression. We performed whole-genome RNA-seq analysis on wild-type Kit + cells expressing BCR-ABL treated with imatinib, DFC + BCI, DFC + BCI + imatinib and nontreated controls. Similarly, BCR-ABL-expressing Kit + cells lacking c-Fos and DUSP1, treated with and without imatinib, were subjected to RNA-seq analysis. We compared gene expression in these samples to that of Kit + cells transduced with the control vector (pMSCV-Ires-GFP) from WT mice. Consistent with the notion that DFC + BCI treatment inhibits c-Fos and Dusp1, we found a striking 
similarity between DFC + BCI-treated WT cells and Fos-and
Dusp1-double-knockout BCR-ABL-expressing cells: 146 genes were regulated in common (58 upregulated and 88 downregulated) relative to those in untreated BCR-ABL-expressing cells (Fig. 5a) . Further analysis of these differentially expressed genes, using Netwalker, suggests that the inhibition of c-Fos and Dusp1 in the context of BCR-ABL expression leads to both downregulation of a Fos-Jun-associated gene network and the induction of a Jun-JunDassociated gene network (Fig. 5b,c) . The AP1 transcription factor is a dimeric complex that contains members of the JUN (JUN, JUNB, and JUND) and FOS (FOS, FOSB, FRA1, and FRA2) protein families 39 . The final outcome of AP1 activity is dependent on AP1 dimer composition, as well as on the cellular and genetic context 24 . Our data show that, in the context of BCR-ABL expression, the absence of c-Fos and Dusp1 results in a net AP1 transcriptional output that is anti-proliferative (reduced expression of Gfi1, Il6, Lif, and Cited2, and overexpression of JunD) and pro-apoptotic (overexpression of BCL2L11) (Fig. 5b,c) . This analysis suggests that acute inhibition of BCR-ABL in c-Fos-and Dusp1-inhibited or c-Fos-and Dusp1-deficient cells undergo apoptotic shock 13, 19 owing to elevated expression of pro-apoptotic genes. for dephosphorylating ERK2 over p38 or JNK 42, 43 , whereas Dusp8, Dusp10 and Dusp16 specifically dephosphorylate JNK and p38 kinases 26 . Similarly, studies from mice lacking Dusp1 have revealed that it preferentially targets p38 and JNK 28, 44 . Overall, Dusp-mediated MAPK regulation is dependent on the cellular, genetic, and signaling contexts 25, 26, 45 .
Dusp6 deficiency confers imatinib resistance
In accord with this complexity, BCI treatment resulted in enhanced phospho-p38 levels in both BaF3 and BaF3-BA cells and decreased phospho-JNK in BaF3-BA cells; the effects in BaF3-BA cells were observed with or without IL-3 co-treatment (Fig. 6a) . Ectopic expression of Dusp1 in BaF3 and BaF3-BA cells reduced phospho-p38 levels, whereas the expression of Dusp6 did not modify the levels of phospho-ERK1/2, phospho-p38 or phospho-JNK in either cell type (Fig. 6b) . Furthermore, overexpression of Dusp1, but not Dusp6, conferred resistance to BCI in BaF3-BA cells (Supplementary Fig. 6a) . These data support the hypothesis that BCI-mediated inhibition of Dusp1 activates p38 to induce TKI sensitivity and suggests that p38 inhibition would confer resistance to imatinib. Accordingly, we found that inhibition of p38 (using SB202190, a derivative of SB203580 46 ), but not inhibition of JNK (using SP600125, which is 100-fold more selective for inhibition of JNK as compared to p38 (ref. 47)), conferred imatinib resistance in BaF3-BA cells (Fig. 6c) . Notably, coexpression of WT Dusp6 with BCR-ABL in WT bone marrow-derived Kit + cells resulted in a significant reduction in CFU formation (~55%, P = 0.001), but did not affect the cells expressing either vector or Dusp1 (Supplementary Fig. 6b) . Importantly, overexpression of Dusp1 but not of Dusp6 conferred resistance to drug (imatinib + BCI) treatment (Supplementary Fig. 6b) . Notably, unlike Dusp1 −/− cells, Dusp6 −/− cells were resistant to drug (imatinib + BCI) treatment and displayed normal CFU activity in comparison to untreated WT cells (Supplementary Fig. 6c ). Moreover, ectopic expression of Dusp6 in Dusp6 -/cells abolished drug resistance and restored TKI sensitivity to a normal level (Supplementary Fig. 6c) . Previous work has shown that Dusp6 expression might be a requirement for oncogenic transformation in B-ALL but not CML 48 , and loss of Dusp6 expression in lung cancer confers TKI resistance 49 . Taken together with these previous results, our data suggest that the inhibition of Dusp6 favors cancer cell survival upon TKI treatment, and conversely, that the inhibition of Dusp1 modulates p38 activity to promote TKI-induced cell death in LICs.
Mutations affecting the allosteric domain of Dusp1 confer resistance to BCI
To determine the relevant target of BCI more conclusively, we performed in vitro drug-resistant screening to select for BCI-resistant mutations in Dusp1. BaF3-BA cells transfected with an expression library of randomly mutagenized Dusp1 construct were used for the selection of mutations conferring resistance to different concentrations of BCI (Supplementary Fig. 6d ). At 1 µM and 1.5 µM BCI, resistant clones emerged with a frequency of 1,200 clones and 27 clones per million cells, respectively, whereas selection at 2 µM of BCI did not yield any resistant clones (Supplementary Fig. 6e ). 27 clones that emerged in 1.5 µM of BCI were randomly selected and further analyzed. Dose-response analysis confirmed their resistance to BCI (Supplementary Fig. 6f) . Sequencing of the Dusp1 gene in these clones identified four different substitution mutations (E19R, C24G, V83G, and E112R) and two deletion mutations at the N terminus (∆2-8 and ∆2-28; Supplementary Fig. 6g ). Because most resistant clones carried two or more mutations, we generated clones with individual mutations for further analysis. Expression of these resistant variants in BaF3-BA cells conferred resistance to BCI ( Supplementary  Fig. 6h) . Notably, the Dusp1-V83G variant demonstrated higher resistance than other tested variants, which potentially explains why it was more frequently observed in the screen ( Supplementary  Fig. 6h) . Similarly, expression of these resistant variants in BCR-ABL expressing BM-derived Kit + cells conferred resistance to BCI treatment, and the Dusp1-V83G variant conferred greater resistance than the other variants tested (Fig. 6d) . We mapped these resistant mutations on a homology-based structural model of Dusp1 and found that they clustered at the N terminus of the allosteric domain (rhodanese domain) rather than at the catalytic domain (Supplementary Fig. 7) . Furthermore, an unbiased docking of BCI using a structural model of the Dusp1 rhodanese domain identified the putative site to which BCI binds, with a predicted free energy of ∆G = -7.63 (Fig. 6e) . Taken together, these data provide clear evidence that BCI-induced cell death is mediated by the inhibition of Dusp1 (rather than of Dusp6).
In vivo inhibition of c-Fos and Dusp1 targets by DFC and BCI
To model the therapeutic potential of c-Fos and Dusp1 inhibition in vivo, we performed a pharmacodynamic analysis for BCI and DFC. We obtained peripheral blood mononuclear cells 6 h before and after BCI injection, and measured the levels of phospho-p38 and of the c-Fos-target genes Bcl2l11, Il6, and Lif (Fig. 6f,g) . As expected, cells from mice injected with BCI showed an increase (by 4-8 fold) in phospho-p38 levels (Fig. 6f) . Moreover, treatment with DFC + BCI induced Bcl2l11 expression while dampening the expression of Lif and Il6 (Fig. 6g) . Notably, elevated serum IL-6 levels have been reported to be required for leukemic disease development 50, 51 , and IL-6-neutralizing antibodies can suppress disease development 52 . Our data suggest that these markers (phospho-p38, IL6, and Lif) could potentially help to test the efficacy of c-Fos and Dusp1 inhibition and evaluate disease progression.
Deletion of Fos and Dusp1 blocks BCR-ABL-induced B-ALL development Given that growth-factor signaling mediates intrinsic resistance to TKI therapy in both leukemia and solid organ tumors [20] [21] [22] , we reasoned that c-FOS and DUSP1 might have crucial roles in other types of kinase-driven leukemia. First, we tested the roles of Fos and Dusp1 in BCR-ABL-induced B-ALL, which, similarly to BCR-ABL-induced CML, is driven by a diverse spectrum of oncogenic tyrosine kinases and cytokine receptors 53 ; moreover, similarly to BCR-ABL-induced CML, most patients with BCR-ABL-induced B-ALL relapse under TKI treatment 54 . To model B-ALL in vivo in mice, we used bone marrow-derived mononuclear cells (MNCs) from WT and ROSACre ERT2 Fos fl/fl ;Dusp1 −/− mice transduced with BCR-ABL-Ires-YFP (P190) retroviruses 55 . Fos was deleted after 2 weeks of transplantation by tamoxifen injection.
Recipients of WT BM-derived cells developed lethal leukemia with a disease latency of 4-5 weeks; by contrast, the deletion of both Fos and Dusp1 led to complete suppression of disease development and the eradication of leukemic cells within 3 weeks after tamoxifen injection (Supplementary Fig. 8a-c) . These data provide evidence that loss of c-Fos and Dusp1 together results in synthetic lethality in BCR-ABLexpressing B-ALL cells. Surprisingly, mice that received BCR-ABLtransduced ROSACre ERT2 Fos fl/fl Dusp1 −/− cells, but that were not treated with tamoxifen, did not develop leukemia; leukemic cells disappeared from these mice, although with a delayed latency when compared to tamoxifen-treated mice (Supplementary Fig. 8a-c) , most likely owing to lower Fos mRNA expression in these mice as compared to WT mice (Supplementary Fig. 3e ). Taken together, these data suggest that, unlike in CML, deletion of Fos and Dusp1 are sufficient to completely eradicate BCR-ABL-induced B-ALL.
Induction of c-Fos and Dusp1 by the oncogenic kinases FLT3-ITD and JAK2-V617F
Next, we analyzed whether growth-factor signaling can confer resistance to the inhibitors of the oncogenic kinases Flt3 and Jak2. As expected, growth-factor signaling conferred resistance to the Flt3 inhibitor AC220 and the Jak2 inhibitor ruxolitinib in BaF3-FLT3-ITD and BaF3-Jak2-V617F cells, respectively ( Supplementary  Fig. 8d,f) . Similarly to BCR-ABL, the expression of FLT3-ITD and JAK2-V617F induced the expression of c-Fos and Dusp1 (Supplementary Fig. 8e,g) . This induction suggests a more general role for c-Fos and Dusp1 in TKI resistance, which will need to be tested further in animal models.
c-Fos and Dusp1 in normal hematopoietic cells Both HSCs and LSCs (BCR-ABL-expressing HSCs) are dependent on growth factor-signaling, which suggests that elevated Fos and Dusp1 expression in these cells confer intrinsic resistance to TKI. As expected, we found that HSCs have higher levels of FOS and DUSP1 in both humans and mice 56 (Supplementary Fig. 9a,b) . Expression of BCR-ABL in mouse hematopoietic stem and progenitor cells (LSK cells) induced expression of c-Fos and Dusp1, as compared to vectortransduced LSK cells (Supplementary Fig. 9c) , perhaps owing to the convergence of oncogenic and growth-factor signaling at these signaling nodes. Similarly, LSCs (CD34 + and CD38cells) from patients with CML showed higher expression of FOS and DUSP1 as compared to normal HSCs (CD34 + and CD38 − cells) (Supplementary Fig. 9d ).
Growth factor signaling induces pro-survival and anti-apoptotic genes Expression analysis of BaF3-LTBA cells treated with IL-3 showed that higher Fos and Dusp1 expression, as compared to untreated BaF3-LTBA cells (Supplementary Fig. 1c ), is correlated with induced expression of pro-survival and anti-apoptotic genes (Supplementary Fig. 9e) , which might represent a protective mechanism. Notably, expression of these pro-survival and anti-apoptotic genes is dependent upon Fos and Dusp1 function, as shown using FOS and DUSP1 inhibitors ( Supplementary Fig. 9e,f) . Taken together, these data provide evidence that higher levels of Fos and Dusp1 are required to maintain growthfactor-induced expression of pro-survival and anti-apoptotic genes.
DISCUSSION
Initial excitement over the targeting of BCR-ABL with imatinib, a small-molecule TKI, has been tempered by the observation that LSCs from patients with CML can survive TKI treatment. Although this resistance was first thought to be due perhaps to incomplete inhibition of kinase activity, given that LSCs under imatinib treatment displayed residual kinase activity, later studies showed that LSCs survive even when treated with a next-generation BCR-ABL inhibitor, such as nilotinib, which fully quenches kinase activity in vivo 57 . One could conclude from these data that LSCs are not oncogene dependent. According to our model ( Supplementary Fig. 9g-i) , the expression of an activated kinase such as BCR-ABL usurps c-Fos-and Dusp1mediated regulation of cell proliferation and survival. TKI treatment downregulates c-Fos and Dusp1 expression, leading to apoptosis in the bulk tumor; however, within TKI resistant cells (LSCs or BaF3-BA cells treated with IL3), growth-factor signaling can rescue c-Fos and Dusp1 expression, leading to sustained expression of pro-survival and anti-apoptotic genes and TKI resistance. Previous work showing a lack of addiction to BCR-ABL in LSCs from patients with CML prompted many researchers to identify pathways and potential therapeutic targets in these LSCs, such as phosphoinositide 3-kinase (PI3K)-AKT serine/threonine kinase 1 (AKT1); transforming growth factor (TGF)-β-Forkhead box O (FoxO), Hedgehog, and Wnt-β-catenin pathways 58 . Although inhibition of these targets either alone or in combination with kinase inhibitors inhibits the survival of LSCs, such therapy has been shown to be detrimental to normal HSCs, because of the requirement of the targeted pathways for cell survival and self-renewal pathways in normal HSCs.
Our study shows that c-FOS and DUSP1 are activated by both kinase oncoproteins and growth factors, and that their expression levels are uniquely critical for the maintenance of growth-factormediated rescue of MRD in mouse models of TKI-treated leukemia. Moreover, our data show that normal HSCs do not have a critical requirement for c-Fos and Dusp1, given that BM-derived cells lacking Fos and Dusp1 do not show any functional impairment, as assessed by transplantation experiments. We speculate that kinase-driven LSCs differ from normal HSCs because they have adapted to chronic kinase signaling and have become addicted to elevated c-Fos and Dusp1 activity, a growth-factor-induced signaling node. The levels of c-Fos and Dusp1 might dictate the threshold of TKI efficacy, such that lower levels confer sensitivity, whereas higher levels drive intrinsic resistance that leads to MRD in leukemia, and perhaps, in solid organ cancers. Thus, these proteins may represent a unifying Achilles' heel of kinase-driven cancers. Our findings provide proof of principle that MRD can be treated through the inhibition of a convergent signaling node that mediates growth-factor-dependence in kinase-induced leukemia.
METHODS
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper.
Note: Any Supplementary Information and Source Data files are available in the online version of the paper. expressed were created using filtered genes with fold-change analysis between the cells grown with or without the growth factors for all three of the experiments. The fold-change cut-off was set to 1.5 for experiment 1 and was set to 2.0 for experiments 2 and 3. A published data set (GSE12211) that describes gene expression of CML-CD34 + cells during imatinib therapy 23 was similarly analyzed using GeneSpring GX software. The samples were normalized to the median of control sample and filtered on the basis of expression, and genes with probeintensity values below the 50th percentile in at least one condition were eliminated. Gene lists were created containing genes that were differentially expressed by more than 2.0-fold between imatinib-treated and untreated samples. Finally, to identify commonly regulated genes in all four data sets, data sets were analyzed in GeneSpring GX, and the results are presented as a Venn diagram. The data reported in the manuscript are available in the GEO database (GSE75058).
LTC-IC assay. The LTC-IC assay was performed according to the instruction manual of StemCell Technologies. 5,000 CD34 + cells from patient CP4 or 1 million total MNCs from patient CP1 were cultured in StemSpan SFEM medium containing 50 ng/ml SCF, 5 ng/ml IL-3, 20 ng/ml IL-6, 50 ng/ml Flt3L, and 100 ng/ml GM-CSF for 24 h in the following conditions: untreated; imatinib (3 µM), DFC (200 nM) + BCI (500 nM), and imatinib (3 µM) + DFC (200 nM) + BCI (500 nM). After 24 h, the cells were washed in human long-term culture medium (HLTM; MyeloCult H5100 media containing 1 µM hydrocortisone) and were plated on irradiated MS-5 stromal cells. Cultures were maintained for 5 weeks with weekly half-medium changes. Cells were then harvested, counted, and transferred to methylcellulose-containing media (MethoCult Express, StemCell Technologies) for colony-forming assays. At the end of week 5, adherent and nonadherent cells were isolated and plated in methylcellulose (METHOCULT H4434 classic, stem cell technology) for CFU analysis in triplicate. Plates were incubated at 37 °C, and colonies were scored 2 weeks after plating.
Pharmacodynamic analysis of Dusp1 and c-Fos targets. Phospho-p38 analysis.
Three leukemic mice (8-12 weeks old), which had received transplants of BCR-ABL-expressing Kit + cells, were injected with BCI (10 mg/kg) by intraperitoneal injection 4 weeks after transplantation. Phospho-p38 levels were quantified in peripheral blood MNCs using the Phosflow kit (BD Biosciences), according to the supplier's instructions. In brief, blood was collected from each mouse before and 6 hours after drug injection. Mononuclear cells were isolated by RBC depletion: RBCs were lysed twice using 4 ml Pharmlyse solution (BD Biosciences) per 100 µl of peripheral blood by mixing and incubated on ice for 5 min. After the second lysis step, cell pellets were washed with 1 ml 2% BSA in PBS followed by fixation using 100 µl of fixation and permeabilization solutions (BD Biosciences) for 20 min at 4 °C in the dark. The pellets were washed with 1 ml of 1X BD Perm/wash buffer. After fixation, the cells were blocked using 300 µl 2% BSA in Perm/wash buffer (BD Biosciences) at room temperature for 20 min. The cells were divided into three equal aliquots, 100 µl each (~1 million), and incubated with 1 µl total p-38 antibody, 1 µl phospho-p38 antibody, or 1 µl isotype IgG control, overnight at 4 °C. The cells were then washed and incubated with secondary antibody (1 µl of AlexaFluor-488-conjugated secondary antibody) for 1 h at room temperature. All antibody sources and dilutions are presented in Supplementary Table 3 . Cells were washed once again and suspended in 200 µl PBS. Data were acquired by FACS on Fortessa instrument, and the data were analyzed by FlowJo software. The mean fluorescence intensity (MFI) of the IgG control was deducted from the MFI of the experimental samples. The MFI values of phospho-p38 were normalized to those of total p38 to determine the phospho-p38 levels after BCI injection.
Quantitative gene-expression analysis of target genes. Three mice (8-12 weeks old) with leukemia, which had received transplants of BCR-ABL expressing Kit + cells, were injected with DFC + BCI (10 mg/kg each). Peripheral blood was collected from each mouse before and 6 h after drug injection. Mononuclear cells were isolated by RBC depletion, as above. MNCs were pelleted and resuspended in Qiazol lysis buffer (Qiagen). Total RNA was extracted, followed by cDNA synthesis and qPCR analysis of Bcl2l11, Lif, and Il6 using gene-specific primers ( Supplementary Table 4 ). Drug preparation. All drugs were prepared as 10 mM stocks in DMSO and stored at -20 °C until use. For in vivo injection, the stocks of imatinib and BCI were diluted in PBS, whereas the DFC stock was diluted in alkaline PBS containing 15 mM of sodium hydroxide. All drugs were injected into mice via i.p injection.
FACS analysis.
Peripheral blood (PB) cells were collected from transplant-recipient mice once per week via tail bleeding. 20 µl of blood were lysed using Pharmlyse solution (BD Biosciences), and the remaining mononucleated cells were pelleted by centrifugation. The cell pellets were washed once with cold PBS. The percentage of leukemic chimerism was determined by quantifying the levels of YFP-positive cells (BCR-ABL-Ires-YFP), analyzed by FACS. BM cells from mice transplanted with Scl-ttA-BCR-ABL cells or patient-derived cells were aspirated from the mouse femurs to determine the levels of CD45.2 and human CD45. These BM cells were blocked with FcR block (BD bioscience) followed by staining with anti-mouse FITC labeled CD45.1 and anti-mouse PE CD45.2. All antibody sources and dilutions are presented in Supplementary Table 3 . The FACS analysis was performed on an LSRII instrument, and the data were analyzed using FACSDIVA software.
For the analysis of human grafts, bone marrow cells were aspirated every 2 weeks from femurs of the transplanted mice. RBCs were lysed using RBC lysis buffer as above, and the total MNCs were pelleted by centrifugation. The pellet was washed once with cold 1X PBS. The cells were blocked with human FcR block and mouse FcR Block (Miltenyi Biotec), followed by staining with anti-human CD45 FITC and anti-mouse CD45 APC Cy7 overnight at 4 °C. All antibody sources and dilutions are presented in Supplementary Table 3 . The FACS analysis was performed on an LSRII instrument, and the data were analyzed using FACSDIVA software.
For differential analysis of peripheral blood (PB) cells, 20 µl of blood was lysed using RBC lysis buffer and the TMNCs were pelleted by centrifugation and washing as described above. The cells were then blocked for 10 min at room temperature using mouse FcR blocking reagent (Miltenyi Biotec) followed by staining with the following antibodies for 30 min at 4 °C: anti-CD11b (recognizes monocytes), anti-CD3 (recognizes T cells), anti-B220 (recognizes B cells), and anti-Gr1 (recognizes granulocytes) All antibody sources and dilutions are presented in the Supplementary Table 3 . The FACS analysis was performed on an LSRII instrument, and the data were analyzed using FloJo software.
Random mutagenesis and screening of Dusp1 mutants. A Gateway entry clone containing mouse Dusp1 complementary DNA was purchased from the Harvard PalsmiD repository (cat. #MmCD00312825). The Dusp1 coding region was transferred into the retroviral gateway vector pMSCV-Ires-GFP.GW 59 by recombination cloning. Mutagenesis and resistance screening were performed as described previously 9 . Mutants isolated in the screen were engineered into the pMSCV-Dusp1-Ires-GFP vector, using the QuikChange II XL Site-Directed Mutagenesis Kit (Agilent). The sequence of each point mutation was confirmed by sequence analysis.
Dusp1 structural modeling and inhibitor docking. Structural models of Dusp1 domains were built by homology-based modeling using SWISS-MODEL software, and crystal structures, as described previously 59 . A model of the Dusp1 phosphatase domain was built using the crystal structures of Dusp4 (PDB: 3EZZ; Dusp4 has 85% sequence identity with Dusp1 and Dusp6 (PDB: 1MKP; Dusp6 has 48% sequence identity with Dusp1. The structure of the N-terminal rhodanese domain of Dusp1 was built using the crystal structure of Dusp16 (PDB: 2VSW; the N-terminal domain of Dusp16 has 26% sequence identity to Dusp1). Only three structures of a Dusp allosteric domain are available in the database (for Dusp6, Dusp10, and Dusp16), and a sequence analysis did not show sufficient sequence identity of the Dusp1 rhodanese domain with the N-terminal domains of Dusp6 and Dusp10 (less than 17%); we therefore used only the Dusp16 structure (PDB: 2VSW) to build the model.
Blind docking of BCI to the rhodanese domain model of Dusp1 was performed using SwissDock software 59 . Modules with the most favorable energies were clustered. For each cluster, binding modules with the lowest energy (i.e., the most likely to represent true binding) were selected to validate the model by site-directed mutagenesis, given that mutation V83G conferred resistance to BCI. Figures were generated using PyMol software.
